Trials Sponsors Conditions Drugs Pricing

Conditions

Infectious Diseases of Spine

Outcome Measures

Primary Outcomes (2)

Clearance (L/h)
Through study completion, an average of 30 days
Volume of Distribution (L)
Through study completion, an average of 30 days

Secondary Outcomes (3)

the ratio of the area under the concentration-time curve from 0 to 24 hours
Through study completion, an average of 30 days
erythrocyte sedimentation rate
Through study completion, an average of 30 days
Adverse events
Through study completion, an average of 30 days

Interventions

Anti-Infective DrugsDrug

Anti-infective drugs are administered using the traditional clinical dosing regimen, with no interventions.

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Sexall

Healthy VolunteersNo

Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Patients with suspected/confirmed spinal infections who are undergoing anti-infective drug therapy.

You may qualify if:

Patients with suspected/confirmed spinal infections who are undergoing anti-infective drug therapy.

You may not qualify if:

Sponsors & Collaborators

Shandong University
Otherlead
Shandong Public Health Clinical Center
Governmentcollaborator

Study Sites (1)

Shandong Public Health Clinical Center

Jinan, China

RECRUITING

Qiang ZhangCONTACT

MeSH Terms

Interventions

Anti-Infective Agents

Intervention Hierarchy (Ancestors)

Therapeutic UsesPharmacologic ActionsChemical Actions and Uses

Study Officials

Wei Zhao, Ph.D
Shandong University
PRINCIPAL INVESTIGATOR

Central Study Contacts

Wei Zhao, Ph.D

CONTACT

8653188383308 zhao4wei2@hotmail.com

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Head of department of clinical pharmacy and pharmacology

Study Record Dates

First Submitted

October 28, 2024

First Posted

December 2, 2024

Study Start

October 12, 2024

Actual (reported)

Primary Completion

October 1, 2026

Estimated (date passed)

Model-informed Individualized Treatment of Anti-Infective Drugs in Patients With Spinal Infections

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (3)

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (3)

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

Source record

Locations